ICON Appoints Dr. James Cummings as President of ClinicalRM
January 09 2018 - 5:00AM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and
medical device industries, today announced the appointment of Dr.
James Cummings as President of ClinicalRM. ClinicalRM is a wholly
owned subsidiary of ICON plc, providing full service and functional
research solutions to a range of U.S. Federal Health Agencies.
Dr. Cummings has over 20 years’ experience within the global
health and government research and development industries. He is a
vaccine and infectious disease specialist and most recently led the
Influenza related program at Novavax, Inc, in his role as VP
Clinical Development and Translational Medicine. Dr. Cummings is a
retired Colonel with the US Army and served as Director of the
Department of Defence’s Global Emerging Infectious Surveillance and
Response System (GEIS) and as the Director of Translational
Medicine & Regulated Activities for the Walter Reed Army
Institute of Research (WRAIR).
Dr. Cummings is replacing ClinicalRM founder and CEO, Victoria
Tifft, who will transition her leadership role throughout Q1 2018
and will move to the ClinicalRM Board as a non-executive Director
in February 2018. Dr. Cummings will work closely with the
ClinicalRM Board, Executive Team and ICON Leadership in the
continued development of the ClinicalRM organisation as the CRO of
choice in the government sponsored research sector.
Commenting on the appointment of Dr. Cummings, Colin Stanley,
President, ICON Functional Services, said: “I am pleased that James
has joined ClinicalRM to lead the company’s next stage of
development and that Vicki will continue to provide guidance as a
valuable member of the ClinicalRM Board. James’ knowledge of the
industry, operational experience and understanding of research will
help ICON expand in the government research sector. Furthermore his
expertise will strengthen ICON’s capabilities in vaccines and
infectious disease, both of which are important areas of focus for
government and commercial customers.”
Dr. Cummings commented: “I am excited to take on this unique
challenge to combine ClinicalRM’s extensive sector experience and
reputation, with ICON’s broad, global capabilities to provide a
differentiated service offering to federal health agencies. I look
forward to working with Vicki, the ClinicalRM Board and the wider
ICON team to broaden and deepen our relationships with federal and
commercial research sponsors.”
About ClinicalRM
ClinicalRM, a wholly-owned subsidiary of ICON plc, is a
full-service CRO providing clinical trial and functional services
to government and commercial customers. From international
partnerships and affiliations to government relations and local
alliances, ClinicalRM delivers projects spanning the government,
academic and commercial marketplaces. The company has a distinct
ability to provide boots-on-the-ground and rapid response efforts
to global health crises. More information is at
http://www.clinicalrm.com/
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 97 locations in 38 countries and has approximately
13,100 employees. More information is at http://www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180109005846/en/
ICON Media ContactOlivia PimentaWeber Shandwick+44 (0)207
067 0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024